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Zusammenfassung
Die diesjährige St. Gallen Konsensuskonferenz 2013 für 
das frühe Mammakarzinom gab im Wesentlichen welt-
weit gültige, evidenzbasierte Empfehlungen für die Be-
handlung, mit einem breiten Spektrum an annehmbarer 
klinischer Praxis. Der vorliegende Bericht fasst die Ab-
stimmungsergebnisse des internationalen Panels im 
Hinblick auf Lokaltherapie, endokrine Therapie, Chemo-
therapie, zielgerichtete Therapie und adjuvante Bisphos-
phonatgabe zusammen. Dieser Bericht soll eine rasche 
Übersicht über die Diskussion vor Ort geben. Er kann 
nicht die offizielle St. Gallen Konsensus-Publikation er-
setzen, einige Empfehlungen werden sicher noch über-
arbeitet und geändert werden.
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Summary
The 2013 St. Gallen Consensus Conference on early 
breast cancer provided mostly evidence-based, globally 
valid treatment recommendations for breast cancer care, 
with a broad spectrum of acceptable clinical practice. 
This report summarizes the results of the 2013 inter-
national panel voting procedures with regard to loco- 
regional and endocrine treatment, chemotherapy, tar-
geted therapy as well as adjuvant bisphosphonate use. 
This report is not aimed to replace the official St. Gallen 
Consensus publication, some recommendations may 
even be altered in the final paper, but should serve a pre-
liminary rapid report of this important meeting.
Introduction 
The St. Gallen Consensus Conference 2013 (March 13–16) 
 focused again on therapy recommendations for early breast 
cancer which are based on evidence as well as clinical exper-
tise of the international faculty, predominantly from Europe 
and the USA (table 1). The panel openly disclosed any po-
tential conflict of interest (http://www.oncoconferences.ch); 
the COI committee was again chaired by Harold Burstein 
(Boston, USA). It was recognized as being unavoidable 
that individual panel members have financial relationships 
with commercial organizations engaged in research, innova-
tion, and education. None of the declared conflicts were 
judged to substantially impact the voting procedure and 
 warrant exclusion of a panel member. However, members 
with a specific COI were asked to refrain from voting at 
 certain questions. 
The motto of this year’s conference was: ‘Rational Recom-
mendations – Personalizing the Approach to Treatment of 
Women with Early Breast Cancer’. About 3,500 participants 
from 94 countries saw 2.5 days of high-level educational 
 lectures addressing the local and systemic therapy as well as 
imaging issues. Next to Swiss participants, for the first time 
Chinese delegates constituted the largest group of attendees 
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thereby demonstrating the growing international interest in 
this traditional meeting. 
The Saturday morning consensus panel was again chaired 
by Aaron Goldhirsch (CH/I) and for the first time by Eric 
Winer (USA). Upfront, 12 areas of controversy (table 2) had 
been identified which deserved debate in order to agree on a 
range of solutions suitable for breast cancer care around the 
world. It was stated that clinical trials provide evidence that 
shows whether one treatment is better than another and help 
to estimate an average of outcome improvement, but not on 
how to treat an individual patient. It was stated that treatment 
decisions for an individual patient therefore require inter-
pretation and debate. The primary consideration on which the 
panel’s voting decisions were based upon was to provide a 
treatment choice for women with early breast cancer by con-
sidering tumour biology, tumor extent, risks of therapy and 
patient preference. 
In 2011, the 12th St. Gallen International Breast Cancer 
Conference Expert Panel had suggested for the first time to 
use the intrinsic biological subtypes [1] for developing therapy 
concepts in early breast cancer [2]: strategies for subtypes, 
dealing with the diversity of breast cancer. In addition to the 
topics of intrinsic subtypes, gene signatures and relapse risk, 
as well as systemic therapy covered in 2009 and 2011 [2, 3], 
St. Gallen 2013 also looked closely at controversial issues in 
loco-regional therapy, taking recent data on sentinel node 
 excision and intraoperative radiotherapy into account. 
In order to allow for an informative voting procedure, 
about 100 questions regarding 12 topics had been pre-pre-
pared and agreed on by the panelists. Three possible answers 
were allowed: YES / NO / ABSTAIN. Abstain was to be used 
in case of insufficient data, no expertise on the particular 
issue, or conflict of interest. After each vote, the answers were 
 summarized in percentages. Only brief panel discussions were 
allowed after each topic. This report summarizes the original 
voting questions and resulting percentages of the St. Gallen 
panel discussion on Saturday March 16, 2013. 
Surgery of the Primary Tumor
Again, loco-regional treatment aspects were a major topic of 
this year’s St. Gallen Consensus: Despite extensive discus-
sions, there were no major changes in technical aspects of pri-
mary tumor resection, but it can be noted that oncoplastic 
techniques gain momentum in the field of breast surgery. 
After the pivotal publication of the ACOSOG-011 data in 
2011 [4], many groups and centers have also controversially 
Table 1. Participants of the St. Gallen 2013 international breast cancer 
consensus panel (as announced in the conference program – not all were 
present at the voting process in St. Gallen)
Chairmen
Eric P. Winer (USA) and Aron Goldhirsch (CH/I) 
Panelists
Kathy Albain (USA)
Fabrice André (F)
José Baselga (USA)
Jonas Bergh (S)
Hervé Bonnefoi (F)
Denisse Bretel-Morales (PE)
Harold J. Burstein (USA)
Fatima Cardoso (P)
Monica Castiglione Gertsch (CH)
Alan S. Coates (AUS)
Marco Colleoni (I)
Alberto Costa (I)
Giuseppe Curigliano (I)
Nancy Davidson (USA)
Angelo Di Leo (I)
Bent Ejlertsen (DK)
John F. Forbes (AUS)
Richard D. Gelber (USA)
Michael Gnant (A)
Pamela J. Goodwin (CAN)
Paul E. Goss (USA)
Jay R. Harris (USA)
Daniel F. Hayes (USA)
Clifford A. Hudis (USA)
James N. Ingle (USA)
Jacek Jassem (PL)
Zefei Jiang (CN)
Per Karlsson (S)
Sibylle Loibl (D)
Monica Morrow (USA)
Moise Namer (F)
C. Kent Osborne (USA)
Ann H. Partridge (USA)
Frédérique Penault-Llorca (F)
Charles M. Perou (USA)
Martine Piccart-Gebhart (B)
Kurt Possinger (D)
Kathleen I. Pritchard (CAN)
Emiel J.T. Rutgers (NL)
Felix Sedlmayer (A)
Vladimir Semiglazov (RUS)
Zhi-Ming Shao (CN)
Ian Smith (UK)
Beat Thürlimann (CH)
Masakazu Toi (JPN)
Andrew Tutt (UK)
Michael Untch (D)
Giuseppe Viale (I)
Toru Watanabe (JPN)
Nicholas Wilcken (AUS)
William C. Wood (USA)
Table 2. Twelve areas of controversy as discussed at the panel discussion 
in St. Gallen, Saturday March 16, 2013
 1. Surgery of the primary
 2. Surgery of the axilla
 3. Radiation: partial breast, post-mastectomy, nodal areas,  
advanced technologies
 4. Pathology: Ki-67, ER, HER2, grade, other markers
 5. Multi-gene signatures: 21 gene RS, PAM-50, 70 gene signature, 
EPClin, other
 6. Stroma: extracellular matrix and prognosis
 7. Endocrine therapies: ovarian suppression, tamoxifen,  
aromatase inhibitors
 8. Chemotherapies: luminal A, duration, regimen
 9. Anti-HER2 therapies: combination, duration
10. Neo-adjuvant systemic therapy
11. Bisphosphonates: anti-tumor effects
12. Follow-up after early breast cancer
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discussed [5] and partly or fully implemented new strategies in 
the surgical managements of the axilla. Hence, the operative 
treatment of the axilla again was another main focus in the 
consensus panel, both with respect to sentinel node biopsy 
(SNB) and axillary lymph node dissection (ALND).
Clearly, breast conserving surgery is nowadays the in-
tended standard of care [6], and only marginal areas of con-
troversy remain around the issue. Of note, the consensus 
panel of 2013 sent the strongest signal as of yet that there are 
virtually no absolute contraindications remaining against 
breast conservation. The respective votings (for absolute 
 contraindications) were:
Young age (< 35): 90% NO  6% YES
Young age (< 40): 94% NO  2% YES
Extensive or diffuse microcalcifications: 75% NO 19% YES
Multifocal disease: 89% NO  7% YES
Multicentric disease: 65% NO 30% YES
Tumor close to nipple: 96% NO  0% YES
Extensive vascular invasion: 91% NO  6% YES
Extensive intraductal component: 96% NO  2% YES
Lobular histology: 93% NO  5% YES
With respect to relative contraindications, the consensus panel 
again reiterated that young age in itself is not a contraindica-
tion for breast conservation (< 35 years: 61% NO, 30% YES; 
< 40 years 89% NO, 9% YES), however recommended cau-
tion in the presence of extensive or diffuse microcalcifications 
(70% YES, 15% NO). The panel remained split about multi-
focality as relative contraindication for breast conservation 
(43% YES, 53% NO), but advised caution in the presence of 
true multicentric disease (77% YES, 16% NO). Also, there 
was no clear opinion about a relative contraindication to 
breast conservation for tumors close to the nipple (43% YES, 
53% NO).
In addition, extensive vascular invasion (26% YES, 69% 
NO), extensive intraductal component (EIC; 35% YES, 63% 
NO), and lobular histology were not considered even relative 
contraindications (5% YES, 93% NO) for breast conserving 
surgery. Furthermore, a family history of breast cancer was 
clearly not considered a relative contraindication for breast 
conserving surgery (4% YES, 96% NO). The panel remained 
split about BRCA-1 (54% YES, 46% NO) and BRCA-2 
(51% YES, 47% NO) positivity as relative contraindications 
for breast conservation.
The panel very strongly expressed the opinion that breast 
conservation would not be sustainable in situations in which 
surgical margins remained involved despite repeated excisions 
(96% YES, 2% NO).
Despite the increasing focus on the biology of the disease, 
the panel did not feel that unfavorable biology, based on gene 
expression / sequencing, in itself constitutes a relative contra-
indication for breast conservation (6% YES, 94% NO). In the 
extremely rare cases of contraindications against subsequent 
adjuvant radiotherapy, breast conservation might not be the 
treatment of choice (94% YES, 4% NO).
With respect to other surgical issues, the panel stated that 
nipple-sparing mastectomy without radiotherapy would be an 
‘acceptable’ treatment (66% YES, 21% NO), however clearly 
limited this approach (elimination of radiotherapy) to those 
cases where the central histology margin (towards the nipple) 
was proven tumor-free and immediate reconstruction was 
performed (55% YES, 16% NO).
With respect to surgical planning, the panel members sent 
a strong signal that routine MRI (for all patients with newly 
diagnosed breast cancer) should not be performed (10% YES, 
89% NO), also because of the demonstrated false-positive 
rate of MRI with respect to multicentricity in an unselected 
patient population.
The never-ending issue of minimal surgical resection mar-
gins was enriched by yet another panel opinion, probably also 
because several globally renowned surgeons deemed ‘milli-
meter-counting’ anachronistic once again during the main 
 sessions of the meeting: for the invasive component, the panel 
confirmed ‘no ink on invasive tumor’ as the ‘appropriate mini-
mum margin’ (73% YES, 21% NO), however, panel members 
also felt that a 1 mm margin would be appropriate (49% YES, 
26% NO). More extensive margins were no longer considered 
appropriate, e.g. 3 mm (8% YES, 39% NO). Only a minority 
of panel members (42% YES, 52% NO) thought that margins 
with respect to ductal carcinoma in situ should be viewed dif-
ferently. A clear majority of panel members voted that mini-
mal resection margins cannot be defined ‘depending on tumor 
biology’ (18% YES, 78% NO).
Surgery of the Axilla
Since the sentinel node (SN) approach is meanwhile consid-
ered a standard of care (despite many technical details with-
out convincing evidence) for axillary staging, the 2013 consen-
sus panel did neither discuss the principle indication nor 
 technical aspects. However, the ‘ACOSOG-Z011’ question 
prevailed: again, and reiterating their 2011 majority, the panel 
declined that completion axillary dissection can be safely 
avoided in patients with 1–2 positive SNs and mastectomy 
without radiotherapy (4% YES, 91% NO), however was split 
about the issue in the presence of post-mastectomy radiother-
apy (41% YES, 43% NO). The policy of avoiding full axillary 
clearance after 1–2 positive SNs was endorsed in  situations of 
conservative surgery and radiotherapy (73% YES, 21% NO), 
including several comments that the inclusion criteria of avail-
able trial results should be considered.
Additional liberalizations for the indication for ALND 
were clearly declined: The panel stated strongly that ALND 
must be performed in cases of breast conservation who are 
clinically N1 (88% YES, 8% NO), in situations of 3 or more 
positive SNs (96% YES, 5% NO), but also recommended 
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panel felt that MxRT should not be given to patients only on 
the basis of ‘adverse pathology’ such as grade 3 (4% YES, 
92% NO), lymphovascular invasion (19% YES, 77% NO), 
HER2 overexpression (4% YES, 94% NO), or triple negative 
disease (2% YES, 96% NO). In contrast, local factors such as 
tumor size > 5 cm (67% YES, 29% NO) or positive deep/ 
radial margins (82% YES, 11% NO), were considered indica-
tions for MxRT.
With respect to nodal areas to be included into radiation 
fields, the panel in general declined the notion that nodal 
areas should be included in irradiation fields in all patients, 
for the supraclavicular field ( 33% YES, 53% NO) as well as 
the axilla (7% YES, 82% NO) as well as the internal mam-
mary nodes (11% YES, 70% NO). Because of the clear state-
ment on not routinely including the axilla, the panel did not 
specifically vote on the prepared question whether the axilla 
should be irradiated following surgical ALND. The panel re-
jected the idea that the decision about including nodal areas 
into the radiation field should be influenced by response to 
neoadjuvant therapy (33% YES, 56% NO) or the intrinsic 
subtype of the tumor (17% YES, 77% NO).
Pathology
This year, the chapter ‘Prognostic and Predictive Factors’ was 
substituted by a comprehensive ‘Pathology’ chapter. The 
focus of discussion was set on differentiation of intrinsic sub-
types by means of immunohistochemistry, molecular diagnos-
tics and multigene signatures. Also additional factors for 
HER2 determination, and significance of stromal factors were 
discussed. Attention should be paid that in many statements 
of this chapter the indication and type of adjuvant therapy is 
suggested.
Subtypes
Although prospective data are lacking, the majority felt that 
intrinsic subtypes may influence whether or not chemother-
apy is used in the adjuvant regimen (88.9% YES, 6.7% NO). 
However, no strong agreement was achieved about the 
method of subtype definition. While a majority still pled 
against multi-gene expression array profiling being required 
for subtype definition (22.0% YES, 70.0% NO), about half of 
the panel opted for use of a clinic-pathologic definition (e.g., 
St. Gallen 2011) as sufficient for subtype definition (53.1% 
YES, 38.8% NO). Only a minority thought that the choice of 
cytotoxic therapy regimen should be influenced by intrinsic 
subtype (27.7% YES, 68.1% NO). 
Luminal A / Luminal B
In terms of practical purposes, the majority pled for distinc-
tion between ‘luminal A’ and ‘luminal B’ (HER2-negative) 
tumors to be performed by estrogen receptor (ER), proges-
terone receptor (PR) and Ki-67 (72.9% YES, 27.1% NO). 
ALND in situations when information about the number of 
positive nodes (e.g. N4+) would be essential for the choice of 
chemotherapy (60% YES, 39% NO).
Radiotherapy
The 2013 consensus panel spent more time on modern issues 
of breast radiotherapy (RT) than previous panels: In general, 
it tried to find answers to the following questions: Is there a 
patient subgroup that does not need any RT? Is there a suit-
able subgroup for partial breast RT? Which are the risk fac-
tors requiring post-mastectomy RT to chest wall? What are 
indications for RT of the axilla, the supraclavicular field, the 
internal mammary chain? What about 15- and 16-fraction 
schedules for whole breast RT? Is a boost to the tumor bed 
really necessary in women over the age of 50 with radical 
 microscopic resection margins?
The panel answered that there is definitely a patient sub-
group who do not need RT after breast conservation (68% 
YES, 20% NO), however did not vote on details regarding 
characterization of that group. 
Limitations and or abbreviations of radiotherapy are cur-
rently a controversially discussed ‘hot topic’ in the field of 
 locoregional therapy for breast cancer. Consequently, the 
consensus panel took votes on several related issues which 
could be practice-changing: ‘short course radiotherapy’ 
(40 Gy) in 15 fractions was deemed a potential new standard 
strategy for all patients (60% YES, 31% NO), and more 
strongly for some patients (70% YES, 11% NO). Short-course 
radiotherapy was clearly endorsed in situations where a tumor 
bed boost is planned (78% YES, 4% NO).
Partial breast irradiation after breast conserving surgery 
without any external beam therapy (ASTRO/ESTRO) was 
not endorsed in general (36% YES, 41% NO), but was con-
sidered an option in the absence of adverse tumor pathology 
(49% YES, 22% NO). The panel did not vote on intra-opera-
tive radiotherapy.
The consensus panel strongly reiterated that postmastec-
tomy radiotherapy (MxRT) should be considered standard in 
patients with 4+ positive nodes (95% YES, 2% NO), and rec-
ommended MxRT for patients with 1–3 positive nodes with ad-
verse disease biology (62% YES, 32% NO), but not for all pa-
tients with 1–3 positive nodes (30% YES, 64% NO). There was 
only a small majority favoring MxRT in young patients (< 40 
years of age) and 1–3 positive nodes (55% YES, 41% NO).
The panel clearly declined the necessity of postmastectomy 
radiotherapy for N0 patients with less than 8 nodes examined 
(6% YES, 90% NO), but recommended MxRT for cases of a 
positive sentinel node but no ALND performed (64% YES, 
26% NO).
With respect to young patients, the panel declined that 
MxRT would be necessary for all patients below the age of 
40 regardless of nodal status (10% YES, 86% NO). Also, the 
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However, it was clearly stated that it can be safely determined 
only by laboratories participating in quality assurance pro-
grams (88.9% YES, 8.9% NO). Of course, ER and PR alone 
was not considered to be sufficient for that distinction 
(6.1% YES, 91.8% NO), interestingly, also grading was not 
accepted as a substitute for Ki-67 (grade 3 instead of high 
 Ki-67; 36% YES, 64.0% NO). Although current data show 
only weak concordance between immunohistochemical deter-
mination and molecular diagnostics, it was not accepted that 
luminal A and B subtypes can safely be determined only by 
molecular diagnostics (34% YES, 60% NO). 
Multigene Signatures
A major part of the panel discussion was related to the ques-
tion of routine use of multigene signatures. Interestingly, only 
in node-negative ER-positive HER2-negative cases, a slight 
majority would ask for the additional use of multigene sig-
natures (after clinic-pathological assessment) (56.8% YES, 
43.2% NO). However, the majority of the panelists pled 
against application of multigene signatures in nearly all cases 
independently of the intrinsic subtype (0% YES, 97.6% NO), 
they also pled against the use in nearly all ER- and/or PR-
positive (HER2-negative) cases (20.8% YES, 79.2% NO), 
and against the use in node-positive ER-positive HER2-nega-
tive cases (22.2% YES, 77.8% NO). There was an indifferent 
position of the panel concerning the application of multigene 
signatures in nearly all ‘luminal B’ (HER2-negative), but not 
‘luminal A’ cases (44.4% YES, 51.1% NO).
The discussion was then focused on the benefit of available 
multigene signatures with regard to the indication of adjuvant 
chemotherapy in an endocrine responsive (i.e., any expression 
of ER and/or PR) cohort. A majority thought that the 21-gene 
recurrence score would predict chemotherapy response (78% 
YES, 12% NO). However, only a minority of the panelists 
thought that PAM50 (29.5% YES, 40.9% NO), a the 70 gene 
signature (25% YES, 25% NO), or the Endopredict®-derived 
‘EPClin’ algorithm (10.6% YES, 57.4% NO) would predict 
the effect of chemotherapy. Note that a substantial proportion 
of panelists abstained. The votes on the slightly different 
question whether selection of steroid hormone receptor-posi-
tive patients who might forego chemotherapy can be partially 
based on one of these aforementioned signatures brought 
similar results.
Finally, it was asked whether in some endocrine responsive 
cohorts (i.e., with any expression of ER and/or PR), molecu-
lar diagnostics can be omitted. The majority agreed to omit 
molecular diagnostics in patients with tumor size ≤ 1 cm 
(83.9% YES, 12.9% NO) since chemotherapy would not be 
given anyway. On the other hand, the majority also agreed to 
omit molecular diagnostics in patients with inflammatory 
breast cancer (93.8% YES, 4.2% NO) and in patients with 
4 and more tumor infiltrated axillary lymph nodes (91.5% 
YES, 6.4% NO) since chemotherapy in these patients would 
be given anyway. About half of the panelists voted to omit 
 additional molecular diagnostics for giving adjuvant chemo-
therapy anyway if patients had bigger tumors (e.g., > 5 cm; 
52.4% YES, 40.5% NO), or if the tumors had low expression 
of ER (e.g., 5%; 55.8% YES, 44.2% NO). Interestingly, there 
was no majority to recommend adjuvant chemotherapy if 
 tumors were undifferentiated (grade 3; 30.6% YES, 65.3% 
NO) or patients were young (e.g., < 35 years; 24.4% YES, 
75.6% NO). However, it seems to be accepted worldwide that 
presence of 1–3 tumor infiltrated lymph nodes would not be 
an absolute indication for adjuvant chemotherapy (26.3% 
YES, 71.1% NO). 
HER2, Stroma 
With regard to the determination of HER2 status for anti-
HER2 treatment purposes, it was discussed whether addi-
tional information is required. However, neither heterogene-
ity of overexpression of HER2 (23.9% YES, 71.7% NO) nor 
polysomy 17 (10.6% YES, 85.1% NO) was considered manda-
tory additional information. Not even information on con-
comitant ER expression was considered to be necessary for 
treatment decision (40.5% YES, 59.5% NO). Also the degree 
of tumor proliferation was refused as essential information 
(10.4% YES, 89.6% NO).
As a new pathological feature of the tumor, this year the 
consensus panel discussed whether stromal factors should 
 influence therapy choice in routine clinical practice. However, 
none of the discussed factors, neither immunocyte infiltration 
(11.4% YES, 74.3% NO), nor microvascular density (9.5% 
YES, 88.1% NO), nor stromal p16 staining (0% YES, 97.7% 
NO) was accepted.
Endocrine Therapy
Establishing Standards for Premenopausal Patients 
A convincing majority of the panel members (83.3% YES, 
16.7% NO) rated tamoxifen as minimal standard (‘default’) in 
endocrine adjuvant therapy for premenopausal women. In 
view of the recent data of the ATLAS trials, the extension to 
10 years of tamoxifen in all patients remaining premenopausal 
after 5 years would be considered by less than half of the 
 panelists (42.9% YES, 49.0% NO), however, the majority 
confirmed the indication in ‘some’ selected patients (88.9% 
YES, 8.9% NO). Interestingly, the discussion on ovarian 
 function suppression (OFS) in addition to tamoxifen resulted 
not only in objection for all premenopausal patients (14.9% 
YES, 80.9% NO), but also for young premenopausal patients 
(e.g. < 40 years) (40.9% YES, 50% NO).
Although some data and some guidelines [7] support the 
use of gonadotropin releasing hormone (GnRH)-agonists as 
sole therapy in case of contraindications for tamoxifen, the 
option of OFS alone (without tamoxifen) was refused by the 
panel (24% YES, 70% NO). Conversely, the panelists spoke 
for the combination of OFS with aromatase inhibition as a 
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valid option in case of contraindication for tamoxifen (85.1% 
YES, 8.5% NO), but definitely not in all patients (6.3% YES, 
87.5% NO). 
Establishing Standards for Postmenopausal Patients
After the passionate discussion on aromatase inhibition 
 during the last decade, the debate is calming down to the 
 essential questions on endocrine therapy. The decision on 
standards in endocrine therapy for postmenopausal patients 
presumably represents the general practice: some patients can 
be adequately treated with tamoxifen alone (63.6% YES, 
6.4% NO). If aromatase inhibition is preferred, it needs to be 
started upfront at least in high-risk patients (87.2% YES, 
10.6% NO), but not in all patients (47.5% YES, 50.0% NO). 
Although no data were added to the results of BIG 1-98, 
a majority of the panelists argued for replacing upfront aro-
matase inhibitors by tamoxifen after 2 years (68.1% YES, 
29.8% NO).
There was a slight majority that would offer extended 
 aromatase inhibition beyond 5 years of adjuvant endocrine 
treatment to patients with node-positive disease (57.8% YES, 
17.8% NO), but not to patients with node-negative disease 
(25.5% YES, 66.0% NO).
The panel differentiated the recommendation depending 
on the type of prior endocrine therapy. Thus, a clear majority 
opted for recommending extended aromatase inhibition after 
5 years adjuvant tamoxifen (83.3% YES, 11.9% NO) and also 
for those patients who switched from tamoxifen to an aroma-
tase inhibitor (73.3% YES, 11.1% NO). However, the panel 
majority would not recommend extension of aromatase in-
hibition beyond 5 years to patients who had finished prior 
5 year therapy of aromatase inhibitors (35.6% YES, 40.0% 
NO). Finally, it was discussed what to do in case that aro-
matase inhibitors would not be available or not tolerated, 
 including  patients who switched therefore to tamoxifen; 
 although data are lacking, in those patients tamoxifen should 
be continued beyond 5 years of endocrine therapy (78% YES, 
8% NO). 
Adjuvant Chemotherapy 
The panel voted that the following factors argued for inclu-
sion of chemotherapy into systemic therapy although con-
cerns regarding the reproducibility of Ki-67 and grade under 
routine circumstances were raised: 
Histological grade 3 tumor  YES 84.4% NO 13.3%
High Ki-67 YES 75.5%  NO 14.3%
Low hormone receptor status YES 81.6%  NO 12.2%
Positive HER2 status  YES 91.8%  NO  8.2%
Triple negative status  YES 98.0%  NO  0.0%
High 21 gene RS (e.g. > 25)  YES 93.9% NO  4.1%
70 gene high risk YES 63.3% NO 30.6%
Any positive node YES 32.7% NO 67.3%
> 3 positive nodes YES 93.3% NO  6.1%
Lymphovascular invasion  YES 32.0% NO 64.0%
Young age (e.g. < 35 years) YES 46.0% NO 54.0%
As in 2011, the panelists voted again that luminal A tumors 
are less responsive to chemotherapy (83.3% YES). They con-
sidered less intensive chemotherapy (i.e. 4×AC, 6×CMF, 
4×TC) adequate for luminal A tumors (61.7% YES, 25.5% 
NO) and stated that in high-risk luminal A tumors based on 
tumor volume, chemotherapy should be added (60.0% YES, 
22.9% NO). 
With respect to luminal B tumors, luminal B subtype by 
 itself was considered to be sufficient to prescribe chemother-
apy (61.2% YES, 38.8% NO). Ki-67 was stated to be useful in 
defining luminal B subtype (72.9% YES, 20.8% NO). In con-
trast to 2011, the Ki-67 cut-off of 14% was not unanimously 
considered as the appropriate threshold for defining luminal 
B subtype (23.9% YES, 37.0% NO). The majority felt that a 
cutoff between 20% (29.5% YES, 13.6% NO) and 25% 
(13.3% YES, 6.7% NO) was more appropriate. Consequently, 
a higher threshold was not voted on. 
Several questions addressed the type of chemotherapy. For 
luminal B (HER2-negative) tumors, the panel preferred 
 anthracyclines rather than CMF (70.5% YES, 18.2% NO). 
A majority voted for inclusion of taxanes (56.5% YES, 26.1% 
NO) and a chemotherapy duration of at least 6 cycles (50.0% 
YES, 34.8% NO). Dose-dense chemotherapy was not gener-
ally preferred (19.1% YES, 68.1% NO).
For HER2-positive disease, there was no preferred chemo-
therapy regimen (36.4% YES, 61.4% NO). 68% thought that 
the chemotherapy for HER2-positive disease needed to con-
tain anthracyclines (22.0% NO, 10% ABSTAIN) and 93.2% 
thought that taxanes needed to be included (4.5% NO).
For the basal-like or triple-negative (TNBC) phenotype, 
87% of the panel thought that chemotherapy should include 
anthracyclines and taxanes (6.5% NO). No majority was 
found for a regimen with more alkylating agents than for ex-
ample 4×EC (30.0% YES, 47.5% NO). Neither platinum-
based regimens (14.6% YES, 68.8% NO) nor dose-dense 
 chemotherapy requiring growth factors (38.3% YES, 48.9% 
NO) were preferred for this subtype.
Last but not least, 72.7% of the panelists thought that there 
are other reasons besides tumor characteristics to prefer 
 specific chemotherapy regimens:
Women desiring fertility  
preservation  YES 76.2% NO 19.0%
Avoiding alopecia  YES 56.5% NO 41.3%
Comorbidities  YES 100% (One of only  
 two unanimous votes with  
 100% agreement!) 
Age of the patient  YES 64.0% NO 34.0%
Advanced age alone  YES 60.0% NO 37.1%
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Bisphosphonates 
In summary, bisphosphonates were not recommended as 
 adjuvant therapy in addition to endocrine therapy. The first 
question was whether zoledronic acid, given every 6 months 
during adjuvant endocrine therapy, would generally be indi-
cated to improve disease free survival; only a minority favored 
this option (22.5% YES, 70% NO). However, the voting did 
also not result in any subgroup recommendation, neither for 
premenopausal patients receiving GnRH-agonists plus 
tamoxifen (32.5% YES, 58.1% NO), nor for premenopausal 
patients not receiving GnRH ( 6.7% YES, 86.7% NO). Even 
for postmenopausal patients, the indication was not seen by 
the majority (34.0% YES, 61.7% NO). In order to be com-
plete, the panel discussed a potential adjuvant role of deno-
sumab; however, it was nearly consensus that zoledronic acid 
should not be substituted by bisphosphonates (2.2% YES, 
84.4% NO). 
Follow-Up after Early Breast Cancer
For the first time, the St. Gallen consensus panel wanted to 
give recommendations also on aspects of surveillance after 
breast cancer diagnosis and treatment. Most panelists agreed 
that all patients should have regular follow-up visits with their 
surgeon/oncologist after completing their treatment (exclud-
ing those patients with long-term endocrine therapy; 70.4% 
YES, 25.9% NO); however, little more than half of the pan-
elists would also accept the option that regular follow-up 
 supervised by a nurse specialist in person or by telephone 
would be acceptable for surveillance (59.1% YES, 25.9% 
NO). Finally, routine imaging as part of their follow-up apart 
from mammography was discussed and denied (14.9% YES, 
78.7% NO). 
Conclusion
St. Gallen 2013 was an efficiently run consensus panel discus-
sion, giving international expert opinions on 12 therapeuti-
cally relevant topics for early breast cancer. In general, the 
questions have evolved over the last years and managed to 
 incorporate recent clinical discussions and controversies. The 
expert panel provides a corridor for internationally accepted 
management of early breast cancer. Evidence, clinical exper-
tise, availability of certain drugs, diagnostic or therapeutic 
procedures in individual countries as well as patient prefer-
ence will then determine management for the individual pa-
tient. Thus, the St. Gallen Consensus Panel recommendations 
may well differ from national guidelines – this was explicitly 
stated by Eric Winer at the beginning of the Saturday consen-
sus. For the USA, the National Comprehensive Cancer Net-
work (NCCN) provides widely accepted expert guidelines [8]. 
Intrinsic subtype  YES 37.8% NO 53.3%
BRCA carriers  YES 20.8% NO 72.9%
Histological grade 3 tumor  YES 84.4% NO 13.3%
Anti-HER2 Therapy
The second unanimous vote with 100% agreement was the 
confirmation of 1 year of trastuzumab as standard duration in 
early breast cancer. With regard to minimal tumor size (inva-
sive diameter) requiring trastuzumab, 10% voted for 10 mm, 
72.5% for 5 mm, and 17.5% for any size. 87.2% of the 
 panelists thought that trastuzumab should be given concur-
rent with a taxane but only 14.3% thought that it should be 
given concurrently with anthracyclines (86.7% NO). If 
chemo therapy was contraindicated, there was a split vote 
 regarding administration of trastuzumab with endocrine 
 therapy alone in ER-positive disease (50% YES, 50% NO) 
but a majority of NO votes (about 85%) in ER-negative 
 disease. Unfortunately, during these votes the otherwise flaw-
less voting system failed and the panel voted briefly by show 
of hands. 
Neoadjuvant Chemotherapy
As in 2011, neoadjuvant systemic therapy was discussed 
separately but this year’s questions focused more on con-
cepts than substances. Only 50.9% of the panelists thought 
that facilitation of local therapies should be the only aim of 
neoadjuvant chemotherapy (NACT) (45.3% NO). Thus, al-
most half of the panelists acknowledged that NACT had 
other aims than mere local downstaging. 95.2% stated that 
after pCR to a full course of NACT, no subsequent ad-
juvant chemotherapy should be given. Also after failure to 
achieve pCR with a full course of NACT, 82.5% were 
 opposed to subsequent adjuvant chemotherapy (10.0% 
YES). After a short discussion among the panelists, the 
panel emphasized with a 79.2% majority that the full 
course of NACT should be given upfront (10.4% NO) and 
with a 62.2% majority that completion by adjuvant chemo-
therapy should be given if pCR was reached on an incom-
plete course of NACT (26.7% NO). 
With regard to NACT in HER2-positive disease, it should 
contain anti-HER2 drugs (95.9% YES). 54.3% were against 
recommendation of dual HER2-targeting in the preoperative 
setting for HER2-positive disease (37.1% YES). 
Neoadjuvant endocrine therapy was highly accepted as a 
reasonable option (93.8% YES) in postmenopausal patients 
with highly endocrine responsive disease (i.e., strongly posi-
tive receptors, low proliferation). 62.2% of the panelists voted 
for therapy duration until maximal response (26.7% for 4–8 
months, 11.1% for 3–4 months). 
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such as ASCO (American Society of Clinical Oncology) or 
SABCS (San Antonio Breast Cancer Symposium) and thus 
provide a practical framework for evidence-based breast 
 cancer therapy.
For Germany, the annually updated evidence-based Arbeits-
gemeinschaft Gynäkologische Onkologie (AGO) guidelines 
[7] review every year peer-reviewed publications and ab-
stracts from the major international breast cancer conferences 
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